Suppr超能文献

[慢性光化性皮炎:外用他克莫司治疗(2例报告)]

[Chronic actinic dermatitis: treatment with topical tacrolimus (two cases)].

作者信息

Alquier-Bouffard A, Da Costa C Marques, Roger H, Franck F, Taïeb A, Souteyrand P, D'incan M

机构信息

Service de Dermatologie, Université Clermont-Ferrand 1, CHU, Clermont-Ferrand.

出版信息

Ann Dermatol Venereol. 2007 Jun-Jul;134(6-7):555-8. doi: 10.1016/s0151-9638(07)89268-4.

Abstract

BACKGROUND

Chronic actinic dermatitis is usually controlled under systemic immunosuppressive drugs. We report herein two patients successfully treated with topical tacrolimus.

CASE REPORTS

Two men aged 60 and 70 years were treated for chronic actinic dermatitis for two years using systemic immunosuppressive drugs. Due to drug intolerance and treatment resistance, systemic treatment was substituted by topical tacrolimus. Cutaneous lesions improved dramatically within two months but withdrawal of daily application was immediately followed by recurrence of the lesions.

DISCUSSION

Our cases, together with the 10 others reported in the literature, confirm the efficacy of topical tacrolimus in the treatment of chronic actinic dermatitis. Since tacrolimus chiefly targets activated T lymphocytes, it has been successfully deployed in various inflammatory dermatoses and its use is logical in the treatment of chronic actinic dermatitis. While dramatic improvement is achieved within a few weeks in this indication with twice-daily applications of tacrolimus ointment 0.1%, symptoms recur rapidly on dosage reduction, and extremely long-term, or even lifelong, treatment is thus probably needed. Topical tacrolimus application has been shown to be safe for periods of three years. However, the peculiar mechanism of chronic actinic dermatitis with a pronounced imbalance in T-cell subsets raises the question of theoretical risk of carcinogenicity of tacrolimus applications, and this, together with the prolonged duration of treatment, calls for long-term follow-up of chronic actinic dermatitis patients.

摘要

背景

慢性光化性皮炎通常在系统性免疫抑制药物治疗下得到控制。我们在此报告两例成功使用外用他克莫司治疗的病例。

病例报告

两名分别为60岁和70岁的男性,使用系统性免疫抑制药物治疗慢性光化性皮炎两年。由于药物不耐受和治疗抵抗,系统性治疗改为外用他克莫司。皮肤病变在两个月内显著改善,但每日用药停药后病变立即复发。

讨论

我们的病例以及文献中报道的其他10例病例,证实了外用他克莫司治疗慢性光化性皮炎的疗效。由于他克莫司主要作用于活化的T淋巴细胞,它已成功应用于各种炎症性皮肤病,用于治疗慢性光化性皮炎是合理的。虽然使用0.1%他克莫司软膏每日两次应用于该适应症在几周内可取得显著改善,但剂量减少时症状会迅速复发,因此可能需要极长期甚至终身治疗。外用他克莫司已被证明在三年的使用期内是安全的。然而,慢性光化性皮炎具有T细胞亚群明显失衡的特殊机制,这引发了他克莫司应用存在致癌理论风险的问题,再加上治疗时间延长,需要对慢性光化性皮炎患者进行长期随访。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验